<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000538634"><TermName>nimotuzumab</TermName><TermPronunciation>(ny-moh-TOO-zoo-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of some types of cancer. Nimotuzumab binds to a protein called epidermal growth factor receptor (EGFR), which is found on some normal cells and some types of cancer cells. Blocking this protein may help keep cancer cells from growing. Nimotuzumab is a type of monoclonal antibody. Also called Theraloc.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718026" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;nimotuzumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718025" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;nimotuzumab&quot;" language="es" id="_4"/><SpanishTermName>nimotuzumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de algunos tipos de cáncer. El nimotuzumab se une a una proteína que se llama receptor del factor de crecimiento epidérmico (RFCE), que se encuentra en algunos tipos de células normales y en algunos tipos de células cancerosas. El bloqueo de esta proteína puede ayudar a impedir la formación de células cancerosas. El nimotuzumab es un tipo de anticuerpo monoclonal. También se llama Theraloc.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-10-04</DateFirstPublished><DateLastModified>2014-08-13</DateLastModified></GlossaryTerm>
